-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On Coherus Oncology with Buy Rating, Announces Price Target of $12

Benzinga·05/11/2026 18:40:53
Listen to the news
Guggenheim initiates coverage on Coherus Oncology (NASDAQ:CHRS) with a Buy rating and announces Price Target of $12.